Pharma Journalist -

Jazz Pharmaceuticals has agreed to acquire privately held Actio Biosciences in a deal worth up to $1.32 billion, adding an experimental precision medicine for a rare form of epilepsy to…
Read More...

Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement that will give Innovent sole commercialization rights for Vanflyta (quizartinib) in China, expanding the Chinese…
Read More...

Revolution Medicines and BeOne Medicines are joining forces to test new drug combinations aimed at cancers driven by RAS mutations, while also expanding access to Revolution Medicines’…
Read More...

Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku to advance ENERGI-F703DFU, an experimental topical treatment being developed for diabetic foot…
Read More...

Autoimmune T-Cell Engager Field Reaches Defining Moment as Industry Leaders Prepare to Unite in Boston Boston, MA | October 27–29, 2026 The autoimmune T-cell engager field is…
Read More...

FUJIFILM Corporation and Taiho Pharmaceutical have formed a strategic partnership to advance manufacturing technologies for next-generation antibody-drug conjugates (ADCs), aiming to…
Read More...

Amplia Therapeutics has entered into a clinical trial collaboration with Eli Lilly and Company to evaluate a new targeted treatment combination for patients with advanced non-small cell…
Read More...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the…
Read More...

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to combine in a tax-free, all-stock merger of equals that will create a leading biopharmaceutical company focused on…
Read More...

Curium and Lantheus have announced a definitive agreement to combine their businesses in a deal valued at up to approximately $8 billion, creating one of the world's largest…
Read More...